secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0000950170-23-063338
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent Q3 net loss $33.6M; cash runway into 2027 after $300M offering; ALK/ROS1 data positive
--------------------------------------------------------------------------------

- Net loss of $33.6M ($0.59 per share) for Q3 2023; R&D expenses $29.6M, G&A $9.2M.
- Cash, equivalents and marketable securities $413.3M at Sept 30; plus $282M net from Oct 2023 offering, runway to 2027.
- Reported preliminary Phase 1 data for NVL-655 (ALK+) showing activity in heavily pre-treated patients with favorable safety.
- Initiated Phase 2 registrational cohorts for NVL-520 (ROS1+) at 100 mg daily; data update expected in 2024.
- Appointed Perrin Wilson, Ph.D., as SVP of Business Development & Strategy; advancing NVL-330 toward IND.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000095017023063338/0000950170-23-063338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000095017023063338/nuvl-20231114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-063338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer